Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases

Stock Information for Generation Bio Co.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Generation Bio Co.

Generation Bio Announces Third Quarter 2025 Financial Results
Generation Bio Announces CEO Transition
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results
Generation Bio Announces 1-for-10 Reverse Stock Split
Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.